ArticlePsychiatric services (Washington, D.C.)2014
The diminished pipeline for medications to treat mental health and substance use disorders.
Article in Psychiatric services (Washington, D.C.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Effect of an vitamin D deficiency on depressive symptoms in child and adolescent psychiatric patients - a randomized controlled trial: study protocol.BMC psychiatry · 2018Trial
- New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?Pharmaceuticals (Basel, Switzerland) · 2025Review
- Automated speech and language markers of longitudinal changes in psychosis symptoms.NPP - digital psychiatry and neuroscience · 2025Article
- Neuroactive Steroids, Toll-like Receptors, and Neuroimmune Regulation: Insights into Their Impact on Neuropsychiatric Disorders.Life (Basel, Switzerland) · 2024Review
- Review
- Non-invasive temporal interference electrical stimulation of the human hippocampus.Nature neuroscience · 2023Article
- Article
- Investigating Post-translational Modifications in Neuropsychiatric Disease: The Next Frontier in Human Post-mortem Brain Research.Frontiers in molecular neuroscience · 2021Review
- New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy.Frontiers in psychiatry · 2021Article
- The Use of Antidepressants, Anxiolytics, Sedatives and Hypnotics in Europe: Focusing on Mental Health Care in Portugal and Prescribing in Older Patients.International journal of environmental research and public health · 2020Article
- Rodent models of post-traumatic stress disorder: behavioral assessment.Translational psychiatry · 2020Review
- The Promise of Automated Home-Cage Monitoring in Improving Translational Utility of Psychiatric Research in Rodents.Frontiers in neuroscience · 2020Review
- Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats.Neuropharmacology · 2019Review
- Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development.Methods in molecular biology (Clifton, N.J.) · 2019Review
- The Microbiome and Mental Health: Looking Back, Moving Forward with Lessons from Allergic Diseases.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2016Review
- Neuroscience and the future for mental health?Epidemiology and psychiatric sciences · 2016Article
- Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.The journal of mental health policy and economics · 2015Article
- Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases.Innovations in clinical neuroscienceArticle
- A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.Journal of psychoactive drugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivePsychotropic drug development is perceived to be lagging behind other pharmaceutical development, even though there is a need for more effective psychotropic medications. This study examined the state of the current psychotropic drug pipeline and potential barriers to psychotropic drug development.
methodsThe authors scanned the recent academic and "grey" literature to evaluate psychotropic drug development and to identify experts in the fields of psychiatry and substance use disorder treatment and psychotropic drug development. On the basis of that preliminary research, the authors interviewed six experts and analyzed drugs being studied for treatment of major psychiatric disorders in phase III clinical trials.
resultsInterviews and review of clinical trials of drugs in phase III of development confirmed that the psychotropic pipeline is slim and that a majority of the drugs in phase III trials are not very innovative. Among the barriers to development are incentives that encourage firms to focus on incremental innovation rather than take risks on radically new approaches. Other barriers include human brain complexity, failure of animal trials to translate well to human trials, and a drug approval threshold that is perceived as so high that it discourages development.
conclusionsDrivers of innovation in psychotropic drug development largely parallel those for other drugs, yet crucial distinctions have led to slowing psychotropic development after a period of innovation and growth. Various factors have acted to dry up the pipeline for psychotropic drugs, with expert opinion suggesting that in the near term, this trend is likely to continue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.